GFACX
Price
$61.91
Change
-$1.33 (-2.10%)
Updated
Sep 6 closing price
LGLUX
Price
$39.33
Change
-$1.02 (-2.53%)
Updated
Sep 6 closing price
Ad is loading...

GFACX vs LGLUX

Header iconGFACX vs LGLUX Comparison
Open Charts GFACX vs LGLUXBanner chart's image
American Funds Growth Fund of Amer C
Price$61.91
Change-$1.33 (-2.10%)
VolumeN/A
CapitalizationN/A
Lord Abbett Growth Leaders R5
Price$39.33
Change-$1.02 (-2.53%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
GFACX vs LGLUX Comparison Chart
Loading...
VS
GFACX vs. LGLUX commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GFACX is a Buy and LGLUX is a Buy.

FUNDAMENTALS
Fundamentals
GFACX has more cash in the bank: 270B vs. LGLUX (5.77B). GFACX (0.00) and LGLUX (0.00) have matching dividends . GFACX was incepted earlier than LGLUX: GFACX (24 years) vs LGLUX (9 years). LGLUX is a more actively managed with annual turnover of: 120.00 vs. GFACX (31.00). LGLUX has a lower initial minimum investment than GFACX: LGLUX (0) vs GFACX (250). LGLUX annual gain was more profitable for investors over the last year : 25.70 vs. GFACX (16.44). GFACX return over 5 years is better than : 38.56 vs. LGLUX (30.71).
GFACXLGLUXGFACX / LGLUX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence24 years9 years-
Gain YTD14.98217.67385%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets270B5.77B4,679%
Annual Yield % from dividends0.000.00-
Returns for 1 year16.4425.7064%
Returns for 3 years-11.08-22.8049%
Returns for 5 years38.5630.71126%
Returns for 10 years42.46N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
KW11.040.03
+0.27%
Kennedy-Wilson Holdings
CTVA55.11-0.39
-0.70%
Corteva
FIVN29.58-0.24
-0.80%
Five9
VEV0.14N/A
-1.68%
Vicinity Motor Corp
ADAP1.11-0.05
-4.31%
Adaptimmune Therapeutics plc